Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Dermavant Sciences

Dermavant Presents ADORING 3 LTE Final Data on Complete Skin Clearance and Treatment-Free Interval for VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as Two Years Old with Atopic Dermatitis at 2024 Fall Clinical Dermatology Conference
From Dermavant Sciences
Via Business Wire
Dermavant Presents Data on Achievement of No-to-Minimal Itch and Sleep Improvement in Atopic Dermatitis Patients as Young as Two Years Old at American College of Allergy, Asthma and Immunology Annual Meeting
From Dermavant Sciences
Via Business Wire
Dermavant Announces Approval of Tapinarof in both Psoriasis and Atopic Dermatitis in Japan
From Dermavant Sciences
Via Business Wire
Dermavant Announces Publication of ADORING 1 & ADORING 2 Pivotal Phase 3 Trials of VTAMA® (tapinarof) cream, 1% for Adults and Children 2 Years of Age and Older with Atopic Dermatitis in JAAD
From Dermavant Sciences
Via Business Wire
Dermavant Announces FDA Acceptance of Supplemental New Drug Application (sNDA) for VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
From Dermavant Sciences
Via Business Wire
Dermavant to Present New ADORING Data Including Treatment of Patients with Skin of Color from Phase 3 Trials of VTAMA® (tapinarof) Cream, 1% in Adults and Children 2 Years of Age and Older with Atopic Dermatitis at the 2024 AAD Annual Meeting
From Dermavant Sciences
Via Business Wire
Dermavant Submits Supplemental New Drug Application (sNDA) to FDA for VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
From Dermavant Sciences
Via Business Wire
Dermavant Announces Positive Data from the ADORING Phase 3 Development Program in Atopic Dermatitis with VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old
From Dermavant Sciences
Via Business Wire
Dermavant Announces Positive Results from Phase 4 Open-Label Trial of VTAMA® (tapinarof) Cream, 1% for the Treatment of Plaque Psoriasis in the Head and Neck Region in Adults
From Dermavant Sciences
Via Business Wire
Dermavant Presents Positive Results from Phase 4 Open-Label Trial of VTAMA® (tapinarof) Cream, 1% for the Treatment of Intertriginous Plaque Psoriasis in Adults at 43rd Annual Fall Clinical Dermatology Conference
From Dermavant Sciences
Via Business Wire
Dermavant to Present New Positive Data from Phase 4, Open Label Trial of VTAMA® (tapinarof) Cream, 1% for Intertriginous Plaque Psoriasis in Adults and Multiple Clinical Trials of VTAMA cream at the 2023 Fall Clinical Dermatology Conference
From Dermavant Sciences
Via Business Wire
Dermavant Champions a Culture that Earns Three Best Workplace Rankings in 2023 by Fortune and Great Place to Work®
From Dermavant Sciences
Via Business Wire
Dermavant Announces New Positive Pruritus Data for VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as Two Years Old with Atopic Dermatitis at the EADV Congress 2023
From Dermavant Sciences
Via Business Wire
Dermavant to Present Data from ADORING 1 and 2 Pivotal Phase 3 Trials of VTAMA® (tapinarof) cream, 1% for Adults and Children as Young as 2 Years Old with Atopic Dermatitis at the 2023 EADV Congress
From Dermavant Sciences
Via Business Wire
Dermavant Appoints John Darden as New Head of Marketing
From Dermavant Sciences
Via Business Wire
Dermavant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old
From Dermavant Sciences
Via Business Wire
Dermavant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old
From Dermavant Sciences
Via Business Wire
Dermavant to Present Data from Multiple Studies of VTAMA® (tapinarof) cream, 1% at the 2023 American Academy of Dermatology Annual Meeting
From Dermavant Sciences
Via Business Wire
Dermavant Completes Enrollment of Two Phase 3 Clinical Trials of VTAMA® (tapinarof) cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children as Young as 2 years old
From Dermavant Sciences
Via Business Wire
Dermavant Launches First Commercial for VTAMA® (tapinarof) cream, 1% as Part of a National, Multimedia Campaign for Adults with Plaque Psoriasis
From Dermavant Sciences
Via Business Wire
Dermavant to Present Data from Multiple Clinical Trials of VTAMA® (tapinarof) cream, 1% at the 2022 Fall Clinical Dermatology Conference
From Dermavant Sciences
Via Business Wire
Fortune and Great Place to Work® Name Dermavant One of the Best Small Workplaces™ and Best Workplaces in Biopharma™ in 2022
From Dermavant Sciences
Via Business Wire
Dermavant to Present New Data from Phase 3 Trial Program of VTAMA® (tapinarof) cream, 1% for Adults with Plaque Psoriasis at the 2022 EADV Congress
From Dermavant Sciences
Via Business Wire
VTAMA® (tapinarof) Cream, 1% PSOARING 3 Final Data Published in JAAD
From Dermavant Sciences
Via Business Wire
Dermavant Showcases New Long-Term Durability and Tolerability Data from Phase 3 PSOARING 3 Trial of Tapinarof Cream for Adults with Plaque Psoriasis at the 2022 AAD Annual Meeting
From Dermavant Sciences
Via Business Wire
Dermavant Presents New Patient Satisfaction Data from PSOARING 3 Long Term Extension Trial of Tapinarof in Adults with Plaque Psoriasis at the 2022 Winter Clinical Dermatology Conference
From Dermavant Sciences
Via Business Wire
Dermavant to Present New Data from Phase 3 PSOARING Program at the 2022 Winter Clinical Dermatology Conference
From Dermavant Sciences
Via Business Wire
Dermavant Announces Publication of PSOARING 1 & 2 Pivotal Studies of Tapinarof in Plaque Psoriasis in The New England Journal of Medicine
From Dermavant Sciences
Via Business Wire
Dermavant Showcases New Long-Term Data from Phase 3 PSOARING 3 Trial of Tapinarof in Patients with Plaque Psoriasis at the 30th EADV Virtual Congress
From Dermavant Sciences
Via Business Wire
Dermavant to Present New Data on Phase 3 PSOARING Program at 30th EADV Virtual Congress
From Dermavant Sciences
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.